A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
- Author(s)
- Byeong-Bae Park; Won Seog Kim; Cheolwon Suh; Jung Yong Hong; Deok-Hwan Yang; Won Sik Lee; Young Rok Do; Jong-Ho Won; Min Kyoung Kim; Jae-Cheol Jo; Shin Young Hyun; Jeong-A Kim; Young Ha Oh; Seung-Sook Lee; Young Il Koh
- Keimyung Author(s)
- Do, Young Rok
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Leukemia & Lymphoma
- Issued Date
- 2019
- Keyword
- Lymphoma and Hodgkin disease; neoplasia; salvage therapy; bendamustine
- Abstract
- This trial was designed to investigate the efficacy and toxicity of bendamustine, carboplatin, and dexamethasone (BCD) for relapsed or refractory peripheral T-cell lymphomas (PTCLs), which would be expected to exhibit more promising clinical outcomes compared with bendamustine therapy alone. After treatments with BCD, eight patients exhibited a complete response (CR; 29%) and seven exhibited a partial response (PR; 25%). The overall response rate (ORR) was 54%. Five patients proceeded to ASCT and three patients finally achieved CR. The median progression-free survival (PFS) was 4.4 months (2.8–6.0, 95% CI). For a total of 85 cycles of BCD, grade 3 or 4 neutropenia, thrombocytopenia, and anemia occurred in 17.6, 38.8, and 16.5% of cycles, respectively. Only one patient experienced febrile neutropenia. BCD was a considerable salvage regimen for relapsed or refractory PTCLs with acceptable toxicity; AITL or ASCT eligible patients were more effective to BCD.
- Authorize & License
-
- Authorize공개
- EmbargoForever
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.